Trial Profile
Trimetazidine to prevent myocardial injury or nephropathy in diabetic, renally-impaired patients undergoing percutaneous coronary intervention.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Nov 2015
Price :
$35
*
At a glance
- Drugs Trimetazidine (Primary)
- Indications Myocardial disorders; Renal impairment
- Focus Adverse reactions; Therapeutic Use
- 26 Nov 2015 New trial record